首页> 外文期刊>Virology >Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment on SHIVKU2 infection of rhesus macaques
【24h】

Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment on SHIVKU2 infection of rhesus macaques

机译:瞬时接种替诺福韦[9-R-(2-膦酰甲氧基丙基)腺嘌呤]处理对恒河猴猕猴SHIVKU2感染的持久影响

获取原文
获取原文并翻译 | 示例
       

摘要

SHIVKU2 replicates to high levels in inoculated macaques and reproducibly causes an acute depletion of CD4(+) T cells. We evaluated the ability of treatment with the antiretroviral drug 9-R-(2-phosphonomethoxypropyl)adenine (PMPA; tenofovir), begun 7 days postinoculation, to inhibit viral replication and associated pathogenesis. Highly productive infection (plasma viral RNA > 10(6) copy eq/mL) was present and CD4 depletion had started when treatment was initiated. PMPA treatment was associated with a rapid decline in plasma viral RNA to undetectable levels, with parallel decreases in the infectivity of plasma and infectious cells in PBMCs and CSF and stabilization of CD4(+)T-cell levels. Viral dynamics parameters were calculated for the initial phase of exponential viral replication and the treatment-related decline in plasma viremia. Following cessation of treatment after 12 weeks, plasma viral RNA was detectable intermittently at low levels, and spliced viral transcripts were detected in lymph nodes. Although treatment was begun after viral dissemination, high viremia, and CD4 decreases had occurred, following withdrawal of PMPA, CD4(+) T-cell counts normalized and stabilized in the normal range, despite persistent low-level infection. No PMPA-resistance mutations were detected. These results validate the similar viral replicative dynamics of SHIVKU2 and HIV and SIV, and also underscore the potential for long-term modulation of viral replication patterns and clinical course by perturbation of primary infection. (C) 2000 Academic Press. [References: 38]
机译:SHIVKU2在接种的猕猴中复制至高水平,并可复制地引起CD4(+)T细胞的急性消耗。我们评估了接种后7天开始使用抗逆转录病毒药物9-R-(2-膦酰甲氧基丙基)腺嘌呤(PMPA;替诺福韦)的治疗抑制病毒复制和相关发病机制的能力。存在高产感染(血浆病毒RNA> 10(6)拷贝当量/毫升),开始治疗时CD4耗竭已开始。 PMPA治疗与血浆病毒RNA迅速下降至无法检测的水平,PBMC和CSF中血浆和感染性细胞的感染性平行下降以及CD4(+)T细胞水平的稳定相关。计算指数病毒复制的初始阶段和血浆病毒血症与治疗相关的下降的病毒动力学参数。 12周后停止治疗后,可间歇性检测到低水平的血浆病毒RNA,并在淋巴结中检测到剪接的病毒转录本。尽管治疗是在病毒传播后开始的,但高剂量病毒血症和CD4减少已经发生,撤回PMPA后,尽管持续存在低水平感染,但CD4(+)T细胞计数已恢复正常并稳定在正常范围内。未检测到PMPA抗性突变。这些结果验证了SHIVKU2和HIV和SIV的相似的病毒复制动力学,也强调了通过干扰原发感染对病毒复制模式和临床过程进行长期调节的潜力。 (C)2000年学术出版社。 [参考:38]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号